Търсене на изпитвания

Намерени 4,436 изпитвания Стр. 124 от 222

Набира участници

Upper Extremity Functional Electrical Stimulation (FES) for Restoration of Upper Extremity Function After Spinal Cord Injury (SCI)

Spinal Cord Injuries Peripheral Nerve Injuries

The purpose of this research is to examine the effects that functional electrical stimulation (FES) therapy has on the way the arms, brain and spinal cord work. The study team wants to understand what recovery looks like in persons with a spinal cord injury (SCI) or peripheral nerve injury (PNI) using the MyndMove (MyndTec Inc., Ontario, Canada) therapy system. This type of therapy uses stimulation to help people with SCI and other neurological conditions to perform common tasks, work out, or strengthen muscles.

Начало: 01.11.2024 Край: 31.01.2029 Възраст: 18–70 г.

United States University of Miami NCT06672458

Набира участници

Promoting Mental Health of Teachers and Caregiver Using a Personalized mHealth Toolkit in Uganda

Mental Health Literacy Depression, Anxiety

This study record describes a two-phase of clinical trial study. The first phase is a pilot study phase (to study feasibility and efficacy of the intervention), and the second phase is an effectiveness study phase (a fully powered evaluation study to test the intervention effectiveness). This proposal seeks to develop and test a new mHealth intervention, the mHealth Toolkit for Wellness \& Empowering Lives of School Community (mWEL) in Uganda. The mWEL-digial toolkit is a preventive intervention tool for teachers and parents as a self-help support modality. Caregivers who need support in navigating the toolkit will be supported by peer-community health workers (P-CHWs).

Начало: 01.11.2024 Край: 31.01.2028 Възраст: от 18 г.

Uganda NYU Langone Health NCT06087159

Набира участници

The 5-FU Holter Study

Gastrointestinal Malignancy

To assess the feasibility of using ambulatory ECG monitoring (Holter monitor) for patients receiving 5-FU chemotherapy

Начало: 01.11.2024 Край: 01.01.2026 Възраст: от 18 г. Диагностика

New Zealand University of Auckland, New Zealand NCT06538610

Набира участници Фаза 2/3

Non-Invasive Pulsed Radiofrequency for the Treatment of Neuropathic Pain

Pain, Nerve

The purpose of this study is to examine non-invasive pulsed radiofrequency (NIPRF) and the effect it has on chronic neuropathic pain. Chronic neuropathic pain after peripheral nerve injury most often occurs in the context of post-traumatic or post-surgical pain. It is often treated with nerve blocks, prescription medication, physical therapy, neuromodulation, and surgery. The study team will be examining the efficacy of NIPRF and determining if it would be an appropriate treatment for chronic neuropathic pain after peripheral nerve injury.The Stimpod used in the present study is FDA approved and will be used for on label purposes.

Начало: 01.11.2024 Край: 01.01.2029 Възраст: от 18 г.

United States Stanford University NCT06185816

Набира участници

Analysis of Influencing Factors of High-Order Aberrations of SMILE With Lenticule Retained

Small-incision Lenticule Extraction (SMILE) Surgery Corneal Higher-order Wavefront Aberrations Residual Lenticule

Analysis of Influencing Factors of High-Order Aberrations of SMILE with Lenticule Retained

Начало: 31.10.2024 Край: 31.10.2026 Възраст: 18–45 г.

China Second Affiliated Hospital of Nanchang University NCT06806085

Набира участници Фаза 2

Evaluation of the Possible Safety and Efficacy of Dapagliflozin in the Prophylaxis of Doxorubicin-Induced Cardiotoxicity

Doxorubicin Induced Cardiomyopathy Breast Cancer

This is a randomized controlled clinical trial that aims to evaluate the safety and efficacy of Dapagliflozin as a cardioprotective in doxorubicin-induced cardiotoxicity in breast cancer patients.

Начало: 31.10.2024 Край: 01.10.2026 Възраст: 18–65 г.

Egypt Tanta University NCT06427226

Набира участници Фаза 1

Safety of BBC1501 Intravitreal Injection in Patients With Neovascular Age-Related Macular Degeneration (nAMD)

Age-Related Macular Degeneration

This open-label study is being conducted to evaluate the initial safety and tolerability of BBC1501 IVT in patients with nAMD. The primary objective of this study is to evaluate the safety and tolerability of 3 ascending doses of IVT BBC1501 in patients with nAMD. The secondary objective of this study is to exploratory of BBC1501 efficacy following 3 ascending dose of BBC1501 in nAMD patient.

Начало: 31.10.2024 Край: 01.03.2026 Възраст: от 50 г. Лечение

Australia Benobio Co., Ltd. NCT05803785

Набира участници

Barrigel® PPRT (Post-Prostatectomy Radiation Therapy) Trial

Prostate Cancer

Barrigel is intended to temporarily position the anterior rectal wall away from the prostate or prostate bed during radiotherapy treatment for prostate cancer and, in creating this space, it is the intent of Barrigel to reduce the radiation dose delivered to the anterior rectum.

Начало: 31.10.2024 Край: 31.12.2027 Възраст: от 18 г. Превенция

Australia, United States Palette Life Sciences, Inc. NCT06496256

Набира участници Фаза 2

Reduction of SystemiC Inflammation after ischemic stroke by intravenous DNase administration (ReSCInD)

Reduction of SystemiC Inflammation after ischemic stroke by intravenous DNase administration

Trial status: Authorised All secondary endpoints are analyzed descriptively, and differences between the two study arms are explored according to their level of measurement. The primary endpoint, IL-1 β concentration in the blood within 24±6 hrs after symptom onset, will be analyzed in the full analysis set, which comes as close as possible to the IIT principle. A mixed linear regression model is calculated with the IL-1 β value (at 24±6hrs & 3 d) as the dependent variable, the randomized group, the IL-1 β value at baseline & the time point, the interaction of time + group, as independent variables and the patient as a random effect.

Начало: 31.10.2024 Възраст: от 18 г.

Germany Klinikum der Universitaet Muenchen AöR 2024-516701-22-00

Набира участници Фаза 1

89Zr-olaratumab Dosimetry in Participants With Soft Tissue Sarcoma

Soft Tissue Sarcoma

Soft Tissue Sarcoma (STS) is a type of cancer that develops in soft tissues such as muscles, tendons, fat, blood vessels, and nerves. STSs generally express a protein called Platelet-Derived Growth Factor Receptor (PDGFR)α, which makes them a target for the development of STS therapies, such as olaratumab. Olaratumab has been identified as a promising candidate to which radioactive substances can be attached for imaging or therapeutic purposes. Thus, this first in human imaging trial aims to study olaratumab combined with a radioactive metal called zirconium-89 (89Zr-TLX300-CDx) as a potential new product that may be used for STS imaging and identification of patients that may benefit from future treatments targeting PDGFRα.

Начало: 31.10.2024 Край: 01.08.2026 Възраст: от 18 г. Диагностика

Australia Telix Pharmaceuticals (Innovations) Pty Ltd NCT06537596

Набира участници Фаза 1

A Study of DM005 in Patients With Advanced Solid Tumors

Carcinoma, Non-Small-Cell Lung Squamous Cell Carcinoma of Head and Neck Solid Carcinoma

The goal of this clinical trial is to find out about the safety, efficacy, and tolerability of DM005 for patients with the advanced solid tumors. DM005 is an experimental drug which is not approved by health authorities for the treatment of advanced solid tumors. For each participant, there will be a screening period of up to 28 days, a treatment period consisting of 21-day cycles, an end of treatment (EOT) Visit (+7 days), and a Follow-up Visit at 30 days (±7 days) after the EOT Visit. Participants with advanced solid malignant tumors will be treated with DM005 on Day 1 of each cycle (every 3 weeks, Q3W). An initial dose of DM005 will be infused intravenously (IV) into each participant for approximately 60 minutes (±10) on Cycle1 Day 1. If there is no infusion-related reaction (IRR) during or after the initial dose, with the Investigator's confirmation and supervision, the subsequent dosing of DM005 in the following cycles maybe infused IV for approximately 30 minutes ( ±5). A 21-day observation period (Cycle 1) will then occur, at the end of which all relevant safety data will be reviewed.

Начало: 31.10.2024 Край: 01.03.2027 Възраст: от 18 г. Лечение

Australia, United States Doma Biopharmaceutical（Suzhou）Co., Ltd. NCT06515990

Набира участници Фаза 1

A Study of DR-01 in Subjects With Alopecia Areata and Vitiligo

Alopecia Areata Vitiligo

This is a multi-center, parallel-group, open-label, randomized, Phase 1b study to explore the safety, clinical activity, pharmacokinetics and pharmacodynamics of DR-01 in adults with Alopecia Areata or Vitiligo.

Начало: 30.10.2024 Край: 01.09.2026 Възраст: от 18 г. Лечение

Australia, New Zealand, United States Dren Bio NCT06602232

Набира участници

Multicenter iTBS Neuromodulation for PTSD Treatment

Posttraumatic Stress Disorder

The proposed study aims to evaluate the efficacy of intermittent theta-burst transcranial magnetic stimulation (iTBS) targeting primary motor cortex (M1) as adjunct treatment for PTSD patients. The primary outcome measure includes changes in PTSD symptom severity, with secondary outcome measures focusing on negative moods improvements, quality of life and social/occupation functioning and functional connectivity of the brain.

Начало: 30.10.2024 Край: 01.06.2027 Възраст: 18–65 г.

China Second Affiliated Hospital, School of Medicine, Zhejian NCT06434766

Набира участници Фаза 1

Phase 1b Study of VERVE-201 in Patients With Refractory Hyperlipidemia

Hypercholesterolemia Hypertriglyceridemia Refractory Hyperlipidemia

VT-20101 is an Open-label, Phase 1b, Single-ascending dose study that will evaluate the safety of VERVE-201 administered to patients with Refractory Hyperlipidemia. VERVE-201 uses base-editing technology designed to inactivate the expression of the ANGPTL3 gene in the liver and lower circulating low-density lipoprotein cholesterol (LDL-C) and triglycerides. This study is designed to determine the safety and pharmacodynamic profile of VERVE-201 in this patient population.

Начало: 30.10.2024 Край: 01.12.2027 Възраст: 18–70 г. Лечение

Australia, Canada, South Africa +1 Verve Therapeutics, Inc. NCT06451770

Набира участници Фаза 1

A Study to Investigate the Safety and Efficacy of SAR446523 Injected Subcutaneously in Adult Participants With Relapsed/Refractory Myeloma

Plasma Cell Myeloma Refractory

This is a first-in-human study of SAR446523 conducted in patients with RRMM. The study consists of two parts: Dose escalation (Part A): In this part, up to several dose levels (DLs) of SAR446523 will be explored to determine the maximum administered dose (MAD), maximum tolerated dose (MTD), and recommended dose range (RDR) of 2 dose regimens which will be tested in the dose optimization part. Dose optimization (Part B): In this part, participants will be randomly assigned in a 1:1 ratio using interactive response technology (IRT) to either one of the chosen dose regimens of SAR446523 (determined from data coming from Part A), to determine the optimal dose as the recommended phase 2 dose (RP2D) of SAR446523.

Начало: 30.10.2024 Край: 16.05.2031 Възраст: от 18 г. Лечение

Australia, Canada, France +4 Sanofi NCT06630806

Набира участници Фаза 2

Individualised Dose Optimisation of Ganciclovir in Immunocompromised Children Trial (ID-MAGIC)

Cytomegalovirus Viraemia

This study is being conducted at seven major children's hospitals in Australia and New Zealand to test a new approach for treating a virus, called cytomegalovirus in children with weakened immune systems. The researchers want to find out if using a web app to customise the dose of a medication called ganciclovir is better at clearing the virus over a six-week period compared to the standard method of giving the medication.

Начало: 29.10.2024 Край: 01.12.2028 Възраст: 1–18 г. Лечение

Australia, New Zealand Murdoch Childrens Research Institute NCT06574789

Набира участници Фаза 2

Efficacy and Safety of HB-1 for Panic Disorder

Panic Disorder Mental Illness

The purpose of this study is to determine the safety and efficacy of HB-1, versus placebo and two monotherapies, in male and female adult patients aged 18 to 65 years, inclusive, with Panic Disorder.

Начало: 29.10.2024 Край: 01.02.2027 Възраст: 18–65 г. Лечение

Australia HB BioTech, LLC NCT06483789

Набира участници Фаза 2

Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis

Scleroderma, Diffuse

The purpose of this study is to evaluate the efficacy, safety and tolerability of rapcabtagene autoleucel (administered once following lymphodepletion) in participants with severe refractory diffuse cutaneous systemic sclerosis relative to rituximab.

Начало: 29.10.2024 Край: 30.08.2032 Възраст: 18–70 г. Лечение

Australia, Brazil, Czechia +13 Novartis Pharmaceuticals NCT06655896

Набира участници Фаза 1

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

Solid Tumor, Adult Metastatic Breast Cancer Advanced Breast Cancer HER2 Mutation-Related Tumors +7

First in human study to evaluate the safety, tolerability, and pharmacokinetics (PK) of BBO-10203, a PI3Kα:RAS breaker, alone and in combination with other anti-cancer agents in patients with advanced solid tumors.

Начало: 29.10.2024 Край: 01.11.2028 Възраст: от 18 г. Лечение

Australia, France, Spain +1 TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeuti NCT06625775

Набира участници Фаза 3

A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants

Crohns Disease Colitis, Ulcerative Arthritis, Psoriatic Arthritis, Juvenile

The purpose of this study is to evaluate long-term safety of subcutaneous guselkumab in pediatric participants with moderately to severely active ulcerative colitis, or moderately to severely active Crohn's disease, or juvenile psoriatic arthritis (jPsA).

Начало: 29.10.2024 Край: 12.12.2031 Възраст: от 3 г. Друго

Argentina, Australia, China +10 Janssen Research & Development, LLC NCT06663332

1 … 122 123 124 125 126 … 222